ITGB3 and osteosarcoma: With respect to ITGB3 specifically, despite previous studies showing that it confers resistance to cisplatin in osteosarcoma [24] and demonstrating the tumor-suppressing impact of ITGB3-KD [31–33], the role of ITGB3 in the radiosensitization of malignancies remains largely unexplored.